Genetic variation in the dopamine pathway and smoking cessation

Pharmacogenomics

Volumn 9, Issue 9, 2008, Pages 1307-1321

  David, Sean P ^a   Munafo, Marcus R ^b  

^a Brown University Center for Primary Care and Prevention   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

COMT; DBH; Dopamine; DRD2; DRD4; MAO; Pharmacogenetics; SLC6A3; Smoking cessation; TH

Indexed keywords

AMFEBUTAMONE; BEFLOXATONE; CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE 2 RECEPTOR; FENFLURAMINE; NICOTINE; NICOTINE PATCH; NORTRIPTYLINE; PLACEBO; VARENICLINE; VENLAFAXINE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; FEASIBILITY STUDY; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LIMBIC SYSTEM; NICOTINE REPLACEMENT THERAPY; PHARMACOGENETICS; PHENOTYPE; PREDICTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT;

BUPROPION; DOPAMINE; GENETIC VARIATION; HUMANS; LINKAGE (GENETICS); QUANTITATIVE TRAIT LOCI; SIGNAL TRANSDUCTION; SMOKING CESSATION;

NICOTIANA TABACUM;

EID: 55449125209     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.9.1307     Document Type: Review

References (114)

1. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R: Mortality from smoking worldwide. Br. Med. Bull. 52, 12-21 (1996).
2. Corrigall WA, Coen KM: Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl.) 104, 171-176 (1991).
3. Corrigall WA, Franklin KB, Coen KM, Clarke PB: The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl.) 107, 285-289 (1992).
4. Laviolette SR, van der Kooy D: Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol. Psychiatry 8, 50-59, (2003).
5. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW: Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 269, 1692-1696 (1995).
6. Picciotto MR, Zoli M, Rimondini R et al.: Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391, 173-177 (1998).
7. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA: Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390, 401-404 (1997).
8. Laviolette SR, van der Kooy D: The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat. Rev. Neurosci. 5, 55-65 (2004).
9. Mansvelder HD, Keath JR, McGehee DS: Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33, 905-919 (2002).
10. Benwell ME, Balfour DJ: The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br. J. Pharmacol. 105, 849-856 (1992).
11. Clarke PB, Fu DS, Jakubovic A, Fibiger HC: Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J. Pharmacol. Exp. Ther. 246, 701-708 (1988).
12. Corrigall WA, Coen KM, Adamson KL: Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res. 653, 278-284 (1994).
13. Balfour DJ: Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. Curr. Drug Targets CNS Neurol. Disord. 1, 413-421 (2002).
14. Benowitz NL: Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 83, 531-541 (2008).
15. Wise RA, Bozarth MA: Brain mechanisms of drug reward and euphoria. Psychiatr. Med. 3, 445-460 (1985).
16. Champagne FA, Chretien P, Stevenson CW, Zhang TY, Gratton A, Meaney MJ: Variations in nucleus accumbens dopamine associated with individual differences in maternal behavior in the rat. J. Neurosci. 24, 4113-4123 (2004).
17. Charara A, Grace AA: Dopamine receptor subtypes selectively modulate excitatory afferents from the hippocampus and amygdala to rat nucleus accumbens neurons. Neuropsychopharmacology 28, 1412-1421 (2003).
18. Khan ZU, Gutierrez A, Martin R, Penafiel A, Rivera A, de la Calle A: Dopamine D5 receptors of rat and human brain. Neuroscience 100, 689-699 (2000).
19. Rivera A, Cuellar B, Giron FJ, Grandy DK, de la Calle A, Moratalla R: Dopamine D4 receptors are heterogeneously distributed in the striosomes/ matrix compartments of the striatum. J. Neurochem. 80, 219-229 (2002).
20. Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA: Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 28, 1272-1280 (2003).
21. Sabol SZ, Nelson ML, Fisher C et al.: A genetic association for cigarette smoking behavior. Health Psychol. 18, 7-13 (1999).
22. Heinz A, Siessmeier T, Wrase J et al.: Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am. J. Psychiatry 161, 1783-1789 (2004).
23. Le Foll B, Diaz J, Sokoloff P: Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 47, 176-183 (2003).
24. Berridge KC, Robinson TE: What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res. Brain Res. Rev, 28, 309-369 (1998).
25. Berlin I, Covey LS, Jiang H, Hamer D: Lack of effect of D2 dopamine receptor TaqI A polymorphism on smoking cessation. Nicotine Tob. Res. 7, 725-728 (2005).
26. Berrettini WH, Wileyto EP, Epstein L et al.: Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol. Psychiatry 61, 111-118 (2007).
27. Cinciripini P, Wetter D, Tomlinson G et al.: The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob. Res. 6, 229-239 (2004).
28. Dahl JP, Jepson C, Levenson R et al.: Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor- 1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics J. 6, 194-199 (2006).
29. David SP, Brown RA, Papandonatos GD et al.: Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob. Res. 9, 821-833 (2007).
30. David SP, Munafo MR, Murphy MF, Proctor M, Walton RT, Johnstone EC: Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J. 8, 122-128 (2008).
31. David SP, Niaura R, Papandonatos GD et al.: Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob. Res. 5, 935-942 (2003).
32. David SP, Strong DR, Munafo MR et al.: Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tab. Res. 9, 1251-1257 (2007).
33. Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafo MR: Association of COMTVa1108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol. Biomarkers Prev. 16, 1065-1069 (2007).
34. Johnstone EC, Yudkin PL, Hey K et al.: Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14, 83-90 (2004).
35. Lerman C, Jepson C, Wileyto EP et al.: Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31, 231-242 (2006).
36. Lerman C, Shields PG, Wileyto EP et al.: Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bapropion clinical trial. Health Psychol. 22, 541-548 (2003).
37. Munafo MR, Johnstone, EC, Guo B, Murphy MF, Aveyard P: Association of COMTVa1108/158Met genotype with smoking cessation. Pharmacogenet. Genomics 18, 121-128 (2008).
38. Robinson JD, Lam CY, Minnix JA et al.: The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. Pharmacogenomics J. 7, 266-274 (2007).
39. Swan GE, Jack LM, Valdes AM et al.: Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol. 26, 361-368 (2007).
40. Swan GE, Valdes AM, Ring HZ et al.: Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J. 5, 21-29 (2005).
41. Yudkin P, Munafo M, Hey K et al.: Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 328, 989-990 (2004).
42. Munafo MR, Johnstone EC, Murphy MF, Aveyard P: Lack of association of DRD2 C32806T (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine Tob. Res. (2008) (In press).
43. O'Gara C, Stapleton J, Sutherland G et al.: Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet. Genomics 17, 61-67 (2007).
44. Ton TG, Rossing MA, Bowen DJ, Srinouanprachan S, Wicklund K, Farin FM: Genetic polymorphisms in dopamine-related genes and smoking cessation in women: a prospective cohort study. Behav. Brain Funct. 3, 22 (2007).
45. Johnstone EC, Yudkin PL, Hey K et al.: Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14, 83-90 (2004).
46. Yudkin PL, Munafò M, Hey K et al.: Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 328(7446), 989-990 (2004).
47. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ: Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch. Gen. Psychiatry 48, 648-654 (1991).
48. Pohjalainen T, Rinne JO, Nagren K et al.: The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 3, 256-260 (1998).
49. Jonsson EG, Nothen MM, Grunhage F et al.: Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 4, 290-296 (1999).
50. Neville MJ, Johnstone EC, Walton RT: Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat. 23, 540-545 (2004).
51. Asghari V, Schoots O, van Kats S et al.: Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol. Pharmacol. 46, 364-373 (1994).
52. van Tol HH, Bunzow JR, Guan HC et al.: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350, 610-614 (1991).
53. van Tol HH, Wu CM, Guan HC et al.: Multiple dopamine D4 receptor variants in the human population. Nature 358, 149-152 (1992).
54. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH: Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J. Neurochem. 65, 1157-1165 (1995).
55. Okuyama Y, Ishiguro H, Toru M, Arinami T: A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem. Biophys. Res. Commun. 258, 292-295 (1999).
56. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE: Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J. Neurosci. 23, 2008-2013 (2003).
57. Shield AJ, Thomae BA, Eckloff BW, Wieben ED, Weinshilboum RM: Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol. Psychiatry 9, 151-160 (2004).
58. Arinami T, Gao M, Hamaguchi H, Toru M: A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 6, 577-582 (1997).
59. Duan J, Wainwright MS, Comeron JM et al.: Synonymous mutations in the human dopamine receptor D2 (DRD1) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 12, 205-216 (2003).
60. Lerman C, Shields PG, Wileyto EP et al.: Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12, 627-634 (2002).
61. Vandenbergh DJ, Persico AM, Hawkins AL et al.: Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14, 1104-1106 (1992).
62. Vandenbergh DJ, Thompson MD, Cook EH et al.: Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations. Mol. Psychiatry 5, 283-292 (2000).
63. Martinez D, Gelernter J, Abi-Dargham A et al.: The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 24, 553-560 (2001).
64. Lerman C, Caporaso NE, Audrain J et al.: Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol. 18, 14-20 (1999).
65. Jorm AF, Henderson AS, Jacomb PA et al.: Association of smoking and personality with a polymorphism of the dopamine transporter gene: results from a community survey. Am. J. Med. Genet. 96, 331-334 (2000).
66. Vandenbergh DJ, Bennett CJ, Grant MD et al.: Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tob. Res. 4, 333-340 (2002).
67. Lang T, Klein K, Fischer J et al.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11, 399-415 (2001).
68. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF: Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain, Neuropharmacology 45, 122-132 (2003).
69. Stapleton JA,. Sutherland G, O'Gara C: Association between dopamine transporter genotypes and smoking cessation: a meta-analysis. Addict. Biol. 12, 221-226 (2007).
70. Bergen AW, Korczak JF, Weissbecker KA, Goldstein AM: A genome-wide search for loci contributing to smoking and alcoholism. Genet. Epidemiol. 17(Suppl. 1), S55-S60 (1999).
71. Bierut LJ, Rice JP, Goate A et al.: A genomic scan for habitual smoking in families of alcoholics: common and specific genetic factors in substance dependence. Am. J. Med. Genet. A 124, 19-27 (2004).
72. Duggirala R, Almasy L, Blangero J: Smoking behavior is under the influence of a major quantitative trait locus on human chromosome 5q. Genet. Epidemiol. 17(Suppl. 1), S139-S144 (1999).
73. Ehlers CL, Wilhelmsen KC: Genomic screen for loci associated with tobacco usage in Mission Indians. BMC Med. Genet. 7, 9 (2006).
74. Ehlers CL, Wilhelmsen KC: Genomic screen for substance dependence and body mass index in southwest California Indians. Genes Brain Behav. 6, 184-191 (2007).
75. Gelernter J, Liu X, Hesselbrock V, Page GP, Goddard A, Zhang H: Results of a genomewide linkage scan: support for chromosomes 9 and 11 loci increasing risk for cigarette smoking. Am. J. Med. Genet. B Neuropsychiatr. Genet. 128, 94-101 (2004).
76. Pomerleau OF, Pomerleau CS, Chu J, Kardia SL: Genome-wide linkage analysis for smoking-related regions, with replication in two ethnically diverse populations. Nicotine Tob. Res. 9, 955-958 (2007).
77. Vink JM, Beem AL, Posthuma D et al.: Linkage analysis of smoking initiation and quantity in Dutch sibling pairs. Pharmacogenomics J. 4, 274-282 (2004).
78. Bergen AW, Yang XR, Bai Y, Beerman MB, Goldstein AM, Goldin LR: Genomic regions linked to alcohol consumption in the Framingham Heart Study. BMC Genet. 4(Suppl. 1), S101 (2003).
79. Goode EL, Badzioch MD, Kim H et al.: Multiple genome-wide analyses of smoking behavior in the Framingham Heart Study. BMC Genet. 4(Suppl. 1), S102 (2003).
80. Morley KI, Medland SE, Ferreira MA et al.: A possible smoking susceptibility locus on chromosome 11p12: evidence from sex-limitation linkage analyses in a sample of Australian twin families. Behav. Genet. 36, 87-99 (2006).
81. Saccone NL, Neuman RJ, Saccone SF, Rice JP: Genetic analysis of maximum cigarette-use phenotypes. BMC Genet. 4(Suppl. 1), S105 (2003).
82. Stallings MC, Corley RP, Hewitt JK et al.: A genome-wide search for quantitative trait loci influencing substance dependence vulnerability in adolescence. Drug Alcohol Depend. 70, 295-307 (2003).
83. Wang D, Ma JZ, Li MD: Mapping and verification of susceptibility loci for smoking quantity using permutation linkage analysis. Pharmacogenomics J. 5, 166-172 (2005).
84. Swan GE, Hops H, Wilhelmsen KC et al.: A genome-wide screen for nicotine dependence susceptibility loci. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B, 354-360 (2006).
85. Gelemter J, Panhuysen C, Weiss R et al.: Genomewide linkage scan for nicotine dependence: identification of a chromosome 5 risk locus. Biol. Psychiatry 61, 119-126 (2007).
86. Loukola A, Broms U, Maunu H et al.: Linkage of nicotine dependence and smoking behavior on 10q, 7q and 11p in twins with homogeneous genetic background, Pharmacogenomics J. 8, 209-219 (2008).
87. Straub RE, Sullivan PF, Ma Y et al.: Susceptibility genes for nicotine dependence: a genome scan and followup in an independent sample suggest that regions on chromosomes 2, 4, 10, 16, 17 and 18 merit further study. Mol. Psychiatry 4, 129-144 (1999).
88. Sullivan PF, Kuo PH, Webb BT et al.: Genomewide linkage survey of nicotine dependence phenotypes. Drug Alcohol Depend. 93, 210-216 (2008).
89. Li MD, Ma JZ, Payne TJ et al.: Genome-wide linkage scan for nicotine dependence in European Americans and its converging results with African Americans in the Mid-South Tobacco Family sample. Mol. Psychiatry 13, 407-416 (2008).
90. Munafo MR, Johnstone EC: Genes and cigarette smoking. Addiction 103, 893-904 (2008).
91. Li MD: Identifying susceptibility loci for nicotine dependence: 2008 update based on recent genome-wide linkage analyses. Hum. Genet. 123, 119-131 (2008).
92. Saccone SF, Pergadia ML, Loukola A et al.: Genetic linkage to chromosome 22q12 for a heavy-smoking quantitative trait in two independent samples. Am. J. Hum. Genet. 80, 856-866 (2007).
93. Bierut LJ, Madden PA, Breslau N et al.: Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum. Mol. Genet. 16, 24-35 (2007).
94. Hung RJ, McKay JD, Gaborieau V et al.: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452, 633-637 (2008).
95. Thorgeirsson TE, Geller F, Sulem P et al.: A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638-642 (2008).
96. Saccone SF, Hinrichs AL, Saccone NL et al.: Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 16, 36-49 (2007).
97. Berrettini W, Yuan X, Tozzi F et al.: α-5/α-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol. Psychiatry 13, 368-373 (2008).
98. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE: Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. BMC Genet. 8,10 (2007).
99. Uhl GR, Liu QR, Drgon T et al.: Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch. Gen. Psychiatry 65, 683-693 (2008).
100. Brown RA, Niaura R, Lloyd-Richardson EE et al.: Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob. Res. 9, 721-730 (2007).
101. Gelernter J, Yu Y, Weiss R et al.: Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Hum. Mol. Genet. 15, 3498-3507 (2006).
102. Flint J, Munafo MR: The endophenotype concept in psychiatric genetics. Psychol. Med. 37, 163-180 (2007).
103. Welton NJ, Johnstone EC, David SP, Munafo MR: A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob. Res. 10, 231-240 (2008).
104. Flint J, Munafo MR: Forum: Interactions between gene and environment. Curr. Opin. Psychiatry 21, 315-317 (2008).
105. Wright AJ, French DP, Weinman J, Marteau TM: Can genetic risk information enhance motivation for smoking cessation? An analogue study. Health Psychol. 25, 740-752 (2006).
106. Wright AJ, Weinman J, Marteau TM: The impact of learning of a genetic predisposition to nicotine dependence: an analogue study. Tob. Control 12, 227-230 (2003).
107. De Francesco L: Genetic profiteering. Nat. Biotechnol. 24, 888-890 (2006).
108. Branca MA: Royal Society puts personalized medicine in perspective. Nat. Rev. Drug Discov. 4, 872-873 (2005).
109. Mayor S: Royal Society predicts that personalised medicines are still decades away. BMJ 331, 656 (2005).
110. Weatherall D: Sir David Weatherall reflects on genetics and personalized medicine. Interviewed by Ulrike Knies-Bamforth. Drug Discov. Today 11, 576-579 (2006).
111. Collins FS, Green ED, Guttmacher AE, Guyer MS: A vision for the future of genomics research. Nature 422, 835-847 (2003).
112. Joshi VA, Kucherlapati R: Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. Pharmacogenomics 8, 1211-1220 (2007).
113. Kucherlapati R: Raju Kucherlapati talks about personalised medicine: breathing new life into old drugs. Interview by Steve Carney. Drug Discov. Today 12, 272-275 (2007).
114. Munafo MR, Lerman C, Niaura R, Shields AE, Swan GE: Smoking cessation treatment: pharmacogenetic assessment. Curr Opin. Mol. Ther. 7, 202-208 (2005).